Why are long-acting beta-adrenoceptor agonists long-acting?
نویسندگان
چکیده
منابع مشابه
Why are long-acting beta-adrenoceptor agonists long-acting?
The extended duration of bronchodilation due to formoterol and salmeterol greatly exceeds that of short acting beta 2-adrenoceptor agonists, such as salbutamol or terbutaline. This extended duration and their capacity to "reassert" airway smooth muscle relaxation in vitro despite repeated washing has prompted considerable debate on the underlying mechanism(s). The comparative pharmacology, and ...
متن کاملSome pharmacodynamic aspects on long-acting beta-adrenoceptor agonists.
1. Formoterol and salmeterol are the first members of a new generation of long-acting beta(2)-adrenoceptor agonists for inhalation. The discovery of the long effect duration of formoterol was made by chance, while the development of salmeterol appeared to follow a purposeful research strategy. 2. Preclinical evaluation predictive of the clinical duration of effect of long-acting bronchodilators...
متن کاملSafety of long-acting beta-agonists.
Beta2-adrenoceptor agonists have been used as bronchodilators in the management of bronchial asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that beta2adrenoceptor agonist use may increase morbidity and mortality1. The long term beta-agonists, salmeterol and formeterol were introduced at the time of heightened concern about safety of beta2 agonist ...
متن کاملLong-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma.
New long-acting beta 2-adrenoceptor agonists, formoterol and salmeterol, may soon appear in several European countries for treatment of asthma. This review examines currently available information and compares the basic pharmacology and describes the clinical effects of these new drugs. The long duration of bronchodilation seen in clinical studies seems to be similar, whereas in isolated tissue...
متن کاملSafety of long-acting beta agonists in adults with asthma.
Practice Pointers Asthma affects 8.2% of the U.S. population, and disproportionately affects those who are poor and black. Despite effective therapies, 3,404 U.S. deaths were attributed to asthma in 2010.1 Two types of inhaled pharmacologic agents are used for asthma control: inhaled corticosteroids and LABAs. Concerns about the safety of LABAs have risen with reports of increased hospital admi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 1994
ISSN: 0000-0000,0903-1936
DOI: 10.1183/09031936.94.07030569